Here are Investing.com’s stocks of the week. Microsoft was one of many tech giants that reported earnings this week, with the company topping profit and revenue expectations. MSFT shares jumped more ...

NEW YORK CITY, NY / ACCESS Newswire / May 2, 2025 / In an era where healthcare is as much about timely access and ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

The company's experimental once-daily version will become the first oral GLP-1 for chronic weight management, if approved.

The company’s health services division Evernorth is doubling down on a reliable growth area: assuaging payer concerns around ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Analysts were rushing to reiterate their conviction in the stock following Thursday’s blow to Zepbound and Lilly shares.

Danish drugmaker Novo Nordisk (NOV: N) has secured a significant advantage in the high-stakes obesity drug market after ...

Eli Lilly rose Friday after topping Wall Street's first-quarter expectations. Eli Lilly stock bounced back after tumbling Thursday after CVS' Caremark selected Novo Nordisk's Wegovy as its preferred ...